Why investors are leaning into direct-to-consumer health
Direct-to-consumer health seemed to come out of nowhere. Once an overlooked category, looked down upon by many traditional health care funds, it’s now proven to be one of the most promising go-to-market strategies in digital health.
There are a few reasons for that. Founders have spent the past decade selling into the employer market, which is now overloaded. These days, benefits managers are utterly overwhelmed by point solutions. Meanwhile, companies like Ro, Curology, GoodRx and others have taken off like a rocket ship by building products that consumers pay for out of their own pocket.
But there are some big (but not insurmountable) challenges with D2C health in the long-run, which is a major reason why a portion of these companies end up selling into payers. Arguably, these products and services are less affordable as they cater to those who can afford to pay cash. Costs to acquire patients have gone up substantially, particularly in the past year, for a variety of reasons. Another problem is that investors will look at the value of a patient over time and aim to maximize that metric, but some users only really need one or two visits. There’s also the role of the clinician to consider as some D2C brands will try to improve their efficiency, which may be ideal for some patients but not others.
`Upcoming Sessions
Live conversations with the people shaping healthcare.
Is It Finally the Moment for Alternative Plan Design?
Register Here Employers are under growing pressure to control healthcare costs while improving access, outcomes, and the member experience. That has renewed
Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s
Register Here The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease.
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&
Peptide Therapy: Where Do We Go From Here?
Watch the full webinar Peptide therapies have moved from niche biohacking circles into mainstream medicine, reshaping conversations around weight management, metabolic health,
Not everyone can access the top 1% of physicians. Will AI change that?
Historically, top-tier medical expertise was limited by wealth and geography. As AI reshapes healthcare delivery, a vital question emerges: can it democratize intelligence to give everyone access to the caliber of care typically reserved for the top 1%?
Privacy AI and the Future of HIPAA
Watch the Full Webinar As AI reshapes healthcare and more patient data flows beyond traditional clinical settings, the rules governing privacy, access,